Cloning, characterization and site-directed mutagenesis of canine renin

Journal of Biochemistry

Volumn 142, Issue 6, 2007, Pages 671-680

  Bukhtiyarov, Yuri ^a   Zecher, Marianne ^a,b   Panemangalore, Reshma ^a   Wu, Zhongren ^a   Bruno, Joseph G ^a   Yuan, Jing ^a   Xu, Zhenrong ^a   Dillard, Lawrence W ^a   McGeehan, Gerard M ^a   Harrison, Richard K ^a,c   Scott, Boyd B ^a  

^a Vitae Pharmaceuticals   (United States)

^b Wyeth Research ^*  (United States)

^c PFIZER INC   (United States)

Author keywords

Hypertension; Proteases; Recombinant canine renin; Renin angiotensin aldosterone system; Renin inhibition; Species specificity

Indexed keywords

ANGIOTENSINOGEN; MUTANT PROTEIN; RENIN; RENIN INHIBITOR; TRYPSIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; EMBRYO; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME KINETICS; ENZYME SPECIFICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; MICHAELIS MENTEN KINETICS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; STEADY STATE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CLONING, MOLECULAR; DOGS; ENZYME INHIBITORS; ENZYME PRECURSORS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RENIN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 38849188537     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvm182     Document Type: Article

References (46)

1. Persson, P.B. (2003) Renin: origin, secretion and synthesis. J. Physiol. 552, 667-671
2. Lavoie, J.L., and Sigmund, C.D. (2003) Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 144, 2179-2183
3. Wood, J.M., Schnell, C.R., Cumin, F., Menard, J., and Webb, R.L. (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens. 23, 417-426
4. Van Tassell, B.W., and Munger, M.A. (2007) Aliskiren for renin inhibition: a new class of antihypertensives. Ann. Pharmacother. 41, 456-464
5. Yokosawa, H., Inagami, T., and Haas, E. (1978) Purification of human renin. Biochem. Biophys. Res. Commun. 83, 306-312
6. Skeggs, L.T., Lentz, K.E., Kahn, J.R., and Hochstrasser, H. (1968) Kinetics of the reaction of renin with nine synthetic peptide substrates. J. Exp. Med. 128, 13-34
7. Paschalidou, K., Neumann, U., Gerhartz, B., and Tzougraki, C. (2004) Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions. Biochem. J. 382, 1031-1038
8. Poe, M., Wu, J.K., Lin, T.Y., Hoogsteen, K., Bull, H.G., and Slater, E.E. (1984) Renin cleavage of a human kidney renin substrate analogous to human angiotensinogen, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-OH, that is human renin specific and is resistant to cathepsin D. Anal. Biochem. 140, 459-467
9. Poulsen, K., Haber, E., and Burton, J. (1976) On the specificity of human renin. Studies with peptide inhibitors. Biochim. Biophys. Acta. 452, 533-537
10. Cumin, F., Le-Nguyen, D., Castro, B., Menard, J., and Corvol, P. (1987) Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. Biochim. Biophys. Acta. 913, 10-19
11. Gradman, A.H., Schmieder, R.E., Lins, R.L., Nussberger, J., Chiang, Y., and Bedigian, M.P. (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018
12. Scott, B.B., McGeehan, G.M., and Harrison, R.K. (2006) Development of inhibitors of the aspartyl protease renin for the treatment of hypertension. Curr. Protein Pept. Sci. 7, 241-254
13. Hollenberg, N.K. (2005) Renin report: spotlight on renin: therapeutic opportunities for renin inhibitors. J. Renin. Angiotensin. Aldosterone. Syst. 6, 107-109
14. Azizi, M., Webb, R., Nussberger, J., and Hollenberg, N.K. (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. 24, 243-256
15. Dzau, V.J., Slater, E.E., and Haber, E. (1979) Complete purification of dog renal renin. Biochemistry 18, 5224-5228
16. Burton, J. and Quinn, T. (1988) The amino-acid residues on the C-terminal side of the cleavage site of angiotensinogen influence the species specificity of reaction with renin. Biochim. Biophys. Acta. 952, 8-12
17. Streatfeild-James, R.M., Williamson, D., Pike, R.N., Tewksbury, D., Carrell, R.W., and Coughlin, P.B. (1998) Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus. FEBS Lett. 436, 267-270
18. Pilote, L., McKercher, G., Thibeault, D., and Lamarre, D. (1995) Enzymatic characterization of purified recombinant human renin. Biochem. Cell Biol. 73, 163-170
19. Yokosawa, H., Holladay, L.A., Inagami, T., Haas, E., and Murakami, K. (1980) Human renal renin. Complete purification and characterization. J. Biol. Chem. 255, 3498-3502
20. Nasir, U.M., Suzuki, F., Nagai, T., Nakagawa, T., and Nakamura, Y. (1999) Tyrosine-83 of human renin contributes to biphasic pH dependence of the renin-angiotensinogen reaction. Biosci. Biotechnol. Biochem. 63, 1143-1145
21. Nasir, U.M., Takahashi, K., Nagai, T., Nakagawa, T., Suzuki, F., and Nakamura, Y. (1998) Two peaks in pH dependence of renin-angiotensinogen reaction. Biosci. Biotechnol. Biochem. 62, 338-340
22. Rahuel, J., Priestle, J.P., and Grutter, M.G. (1991) The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. J. Struct. Biol. 107, 227-236
23. Dealwis, C.G., Frazao, C., Badasso, M., Cooper, J.B., Tickle, I.J., Driessen, H., Blundell, T.L., Murakami, K., Miyazaki, H., Sueiras-Diaz, J. et al. (1994) X-ray analysis at 2.0A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen. J. Mol. Biol. 236, 342-360
24. Cappiello, M.G., Wu, Z., Scott, B.B., McGeehan, G.M., and Harrison, R.K. (2004) Purification and characterization of recombinant human cathepsin E expressed in human kidney cell line 293. Protein Expr. Purif. 37, 53-60
25. Knight, C.G., and Barrett, A.J. (1976) Interaction of human cathepsin D with the inhibitor pepstatin. Biochem. J. 155, 117-125
26. Seelmeier, S., Schmidt, H., Turk, V., and von der Helm, K. (1988) Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl Acad. Sci. USA 85, 6612-6616
27. Eid, M., Evin, G., Castro, B., Menard, J., and Corvol, P. (1981) New renin inhibitors homologous with pepstatin. Biochem. J. 197, 465-471
28. Hiwada, K., Kokubu, T., Murakami, E., Muneta, S., Morisawa, Y., Yabe, Y., Koike, H., and Iijima, Y. (1988) A highly potent and long-acting oral inhibitor of human renin. Hypertension 11, 708-712
29. Gross, F., Lazar, J., and Orth, H. (1972) Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 175, 656
30. Guegan, R., Diaz, J., Cazaubon, C., Beaumont, M., Carlet, C., Clement, J., Demarne, H., Mellet, M., Richaud, J.P., Segondy, D., , et al. (1986) Pepstatin analogues as novel renin inhibitors. J. Med. Chem. 29, 1152-1159
31. O'Brien, E. (2006) Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin. Investig. Drugs 15, 1269-1277
32. Wood, J.M., Maibaum, J., Rahuel, J., Grutter, M.G., Cohen, N.C., Rasetti, V., Ruger, H., Goschke, R., Stutz, S., Fuhrer, W., Schilling, W., Rigollier, P., Yamaguchi, Y., Cumin, F., Baum, H.P., Schnell, C.R., Herold, P., Mah, R., Jensen, C., O'Brien, E., Stanton, A., and Bedigian, M.P. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705
33. Rahuel, J., Rasetti, V., Maibaum, J., Rueger, H., Goschke, R., Cohen, N.C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J.M., and Grutter, M.G. (2000) Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 7, 493-504
34. Leung, D., Abbenante, G., and Fairlie, D.P. (2000) Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305-341
35. Babine, R.E., and Bender, S.L. (1997) Molecular recognition of proteinminus signLigand complexes: applications to drug design. Chem. Rev. 97, 1359-1472
36. Guo, T. (2006) Development of BACE1 inhibitors for Alzheimer's disease. Curr. Med. Chem. 13, 1811-1829
37. Gangloff, A., Garneau, A., Huang, Y.W., Yang, F., and Lin, S.X. (2001) Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochem. J. 356, 269-276
38. Wessale, J.L., Calzadilla, S.V., Boyd, S.A., Baker, W.R., Stein, H.H., Kovar, P.J., Barlow, J., Klinghofer, V., Mantei, R., and Kleinert, H.D. (1993) Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs. J. Cardiovasc. Pharmacol. 22, 644-652
39. Boyd, S.A., Fung, A.K., Baker, W.R., Mantei, R.A., Stein, H.H., Cohen, J., Barlow, J.L., Klinghofer, V., Wessale, J.L., Verburg, K.M. et al. (1994) Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. J. Med. Chem. 37, 2991-3007
40. Kleinert, H.D., Rosenberg, S.H., Baker, W.R., Stein, H.H., Klinghofer, V., Barlow, J., Spina, K., Polakowski, J., Kovar, P., Cohen, J. et al. (1992) Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 257, 1940-1943
41. Wood, J.M., Mah, S.C., Baum, H.P., de Gasparo, M., Cumin, F., Rueger, H., and Nussberger, J. (1990) Evaluation of a potent inhibitor of subprimate and primate renins. J. Pharmacol. Exp. Ther. 253, 513-517
42. Kleinman, E.F., Fray, A.H., Holt, W.F., Kiron, R.M.A., Murphy, W.R., Purcell, I.M., and Rosati, R.L. (1994) CP-71,362, an unusually potent inhibitor of rat and dog renin. Bioorg. Med. Chem. Lett. 4
43. Mangiapane, M.L., MacAndrew, J.T., Ellery, S.S., Smith, A.H., Purcell, I.M., Kleinman, E.F., Holt, W.F., and Murphy, W.R. (1994) CP-71,362: a pentapeptide renin inhibitor selective for the canine enzyme. Clin. Exp. Hypertens. 16, 507-533
44. McMahon, E.G., Yang, P.C., Babler, M.A., Bittner, S.E., Suleymanov, O.D., Cain-Janicki, K.J., Bedell, L.J., Hanson, G.J., and Cook, C.S. (1995) Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs. Hypertension 26, 95-100
45. Etoh, Y., Miyazaki, M., Saitoh, H., and Toda, N. (1993) KRI-1314: an orally effective inhibitor of human renin. Jpn J. Pharmacol. 63, 109-119
46. Miyazaki, M., Etoh, Y., Iizuka, K., and Toda, N. (1989) An orally active renin inhibitor: cyclohexylnorstatine-containing dipeptide (KRI-1314). J. Hypertens. Suppl. 7, S25-27